BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Arthritis
,
Prostate
,
Human chorionic gonadotropin
,
Lovastatin
,
rs6983267
,
CXCL2
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
HLA
Summary
General Info
Curated Studies
Most Correlated Studies
Dendritic cells from PBMCs with plasmacytoid and myeloid lineages
L1000 CMAP Breast cancer MCF7 cells with gene overexpression perturbations
L1000 CMAP Prostate cancer PC3 cells with gene overexpression perturbations (1 of 2)
L1000 CMAP Colorectal cancer HT 29 cells with gene overexpression perturbations
Peripheral blood monocytes response to soluble MHC Class II
Explore Curated Studies Results
Literature
Most Relevant Literature
HLA study in Iranian desert Yazd province inhabitants.
Two novel HLA class I alleles HLA-A*03:409 and -B*49:72 and the extension of the -B*40:19 allele seq…
The HLA diversity of the Anthony Nolan register.
Genomic sequence of the HLA-A*02:01:209 allele identified in a solid organ recipient.
The detection of four novel HLA-A alleles: HLA-A*31:01:48, -A*31:210, -A*31:211 and -A*33:03:54.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Clinical Relevance of Typing HLA-DR7-DQ2
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Meta…
Safety Study of Peptide Cancer Vaccine To Treat HLA-A*02-positive Advanced Non-small Cell Lung Cance…
Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 or A*02-positive Advanced Solid Tumor…
HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ